The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Clin Lung Cancer. 2019 Jan;20(1):e73-e76. doi: 10.1016/j.cllc.2018.09.011. Epub 2018 Sep 21.
No abstract available

Keywords: Acquired resistance; EGFR gene; KIF5B-RET; Lung adenocarcinoma; Novel mechanism.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm / genetics
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Kinesins / genetics*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Mutation / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins c-ret / genetics*

Substances

  • Antineoplastic Agents
  • KIF5B protein, human
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins c-ret
  • RET protein, human
  • Kinesins